4SC initiates dosing in resminostat Phase We/II SHORE research for KRAS-mutant colorectal cancer 4SC AG , a drug discovery and development company, today declared that the first individual has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant tumor. SHORE is usually a randomised, open-label, multi-centre, two-arm Phase I/II study in 70 individuals that will evaluate the efficacy, safety and pharmacokinetics of resminostat, in combination with FOLFIRI, a chemotherapy regimen for the treating colorectal cancer, versus FOLFIRI by itself in the control arm.Ebola outbreak more likely to pass on to more countries Dr Saturday. Holly Dr and Phillips. Tara Narula discuss the Ebola epidemic and the latest findings about low-carb versus low-fat diet plans. Last month, two aid workers who contracted Ebola while employed in Liberia were treated effectively at Emory. A third patient, an American doctor, who’s becoming treated in Nebraska, were better tolerating his experimental treatments Monday, but his recovery continues to be uncertain. The grouped family of Dr. Rick Sacra said he was able to eat breakfast Monday for the first time since arriving Fri at the Nebraska INFIRMARY in Omaha.